Phase Structures and Morphologies Determined by Competitions Among Self-Organization, Crystallization, and Vitrification in a Disordered Poly(Ethylene Oxide)-B-Polystyrene Diblock Copolymer

A poly(ethylene oxide)-b-polystyrene (PEO-b-PS) diblock copolymer having a number-average molecular weight ((M) over bar(n)) of 11000 g/mol in the PEO blocks and an (M) over bar(n) of 5200 g/mol in the PS blocks has been synthesized (with a volume fraction of the PEO blocks of 0.66 in the molten state). Differential scanning calorimetry results show that this copolymer possesses a single endotherm, which is attributed to the melting of the PEG-block crystals. Based on real-time resolved synchrotron small-angle x-ray scattering (SAXS) observations, the diblock copolymer is in a disordered state above the glass transition temperature of the PS-rich phase (T-g(PS)) which has been determined to be 44.0 degrees C during cooling using dilatometer mode in thermomechanical measurements. The order-disorder transition temperature (T-ODT) for this diblock copolymer is thus experimentally inaccessible. Depending upon different isothermal crystallization temperatures quenched from the disordered state (T(q)s), four cases can be investigated in order to understand the phase relationships among self-organization, crystallization of the PEO blocks, and vitrification of the PS-rich phase: the region where the T-q is above the T-g(PS), the regions where the T-q is near but slightly higher or lower than the T-g(PS) ; and the region where the T-q is below the T-g(PS) . Utilizing simultaneous SPXS and wide angle x-ray-diffraction experiments, it can be seen that lamellar crystals of the PEO blocks in the first case grow with little morphological constraint due to initial disordered phase morphology. As the T-q approaches but is still slightly higher than the T-g(PS) , as in the second case, the PEG-block crystals with a greater long period (L) than that of the disordered state start to grow. The initial disordered phase morphology is gradually destroyed, at least to a major extent. When the T-q is near but slightly lower than the T-g(PS), the crystallization takes place largely within the existing phase morphology. Only a gradual shift of the L towards smaller q values can be found with increasing time, which implies that the initial phase morphology is disturbed by the crystallization of the PEO blocks. In the last case, the PEO blocks crystallize under a total constraint provided by the disordered phase morphology due to rapid vitrification of the PS-rich phase. Substantial decrease of crystallinity can be observed in this case. This study also provides experimental evidence that the PS-rich phase size, which is down to 7-8 nm, can still retain bulky glassy properties. [S0163-1829(99)01138-8]

Influence of secondary neutrons induced by proton radiotherapy for cancer patients with implantable cardioverter defibrillators

<p>Abstract</p> <p>Background</p> <p>Although proton radiotherapy is a promising new approach for cancer patients, functional interference is a concern for patients with implantable cardioverter defibrillators (ICDs). The purpose of this study was to clarify the influence of secondary neutrons induced by proton radiotherapy on ICDs.</p> <p>Methods</p> <p>The experimental set-up simulated proton radiotherapy for a patient with an ICD. Four new ICDs were placed 0.3 cm laterally and 3 cm distally outside the radiation field in order to evaluate the influence of secondary neutrons. The cumulative in-field radiation dose was 107 Gy over 10 sessions of irradiation with a dose rate of 2 Gy/min and a field size of 10 × 10 cm². After each radiation fraction, interference with the ICD by the therapy was analyzed by an ICD programmer. The dose distributions of secondary neutrons were estimated by Monte-Carlo simulation.</p> <p>Results</p> <p>The frequency of the power-on reset, the most serious soft error where the programmed pacing mode changes temporarily to a safety back-up mode, was 1 per approximately 50 Gy. The total number of soft errors logged in all devices was 29, which was a rate of 1 soft error per approximately 15 Gy. No permanent device malfunctions were detected. The calculated dose of secondary neutrons per 1 Gy proton dose in the phantom was approximately 1.3-8.9 mSv/Gy.</p> <p>Conclusions</p> <p>With the present experimental settings, the probability was approximately 1 power-on reset per 50 Gy, which was below the dose level (60-80 Gy) generally used in proton radiotherapy. Further quantitative analysis in various settings is needed to establish guidelines regarding proton radiotherapy for cancer patients with ICDs.</p

Diagnostic and clinical significance of Crohn’s disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA:New anti-MZGP2 ELISA in Crohn’s

The recent identification of the pancreas major zymogen granule membrane glycoprotein 2 (MZGP2) as the major autoantigen of pancreatic autoantibody (PAB) has led to the appreciation of anti-MZGP2 antibodies as specific markers of Crohn’s disease (CrD). We have recently developed new, robust, highly sensitive and specific IgA and IgG anti-MZGP2 antibody ELISAs and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date for anti-MZGP2 antibodies. In contrast to currently available anti-MZGP2 ELISAs, the new QUANTA Lite® MZGP2 ELISA (INOVA Diagnostics, San Diego, CA) utilizes the eukaryotically-expressed specific isoform 4 of human GP2 UniProtKB: P55259. A total of 832 sera were studied including 617 consecutive IBD patients (323 CrD and 294 UC) under regular follow-up in a tertiary centre, 112 patients with various diseases, and 103 healthy blood donors. The new ELISA’s calculated AUC was 0.5968, 95% CI (0.5552, 0.6383) for IgA anti-MZGP2 [CD vs non-CD (UC plus controls)] and 0.6236, 95% CI (0.5813, 0.6659) for IgG anti-MZGP2. The sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and the specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 was 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and specificity of 84% (79, 89). Of clinical relevance, IgA anti- MZGP2 antibodies were more prevalent in patients with early disease onset (Montreal classification A1, p=0.011), while patients with localised colonic disease were less likely to be IgG anti-MZGP2 positive. Anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement and stricture formation. Patients with longer disease duration were more likely to have IgG anti-MZGP2 or IgA ASCA antibodies. In conclusion, the new IgA and IgG anti-MZGP2 antibody ELISAs allow accurate autoantibody determination, and can be used as a tool to study the clinical significance and utility of these autoantibodies in patients with IBD